A031501

Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer. Click here to learn more.

CA209-901

A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab, or With Standard of Care Chemotherapy, Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial Cancer. Click here to learn more.


Learn more about Bladder Cancer >

Our Affiliations

 

 QCCA The Cancer FoundationNCI

We’re Here to Help! Click Below to Get Started